FDA and FTC warned SafaLab over unapproved, misbranded COVID-19 drug claims for The Prevention 12 Pak supplements.
What happened
FDA and FTC reviewed SafaLab's websites www.safalab.com and www.weeksmd.com on February 8, 2021. FDA found that www.safalab.com offered The Prevention 12 Pak—a set of 12 supplements—for sale in the U.S. with claims that it could mitigate, prevent, treat, diagnose, or cure COVID-19, and www.weeksmd.com directed consumers to safalab.com to buy it. FDA said the product is an unapproved new drug and a misbranded drug.
What FDA found
FDA says the product is an unapproved new drug—a drug sold without FDA approval—because it was sold with claims to prevent or treat COVID-19.
Federal Food, Drug, and Cosmetic Act section 505(a), 21 U.S.C. § 355(a)FDA says the product is a misbranded drug—a drug with misleading labeling—because its labeling made misleading COVID-19 prevention or treatment claims.
Federal Food, Drug, and Cosmetic Act section 502, 21 U.S.C. § 352Introducing the product into interstate commerce is prohibited.
Federal Food, Drug, and Cosmetic Act sections 301(a) and (d), 21 U.S.C. § 331(a) and (d)The FTC Act prohibits advertising that a product can prevent, treat, or cure human disease without competent and reliable scientific evidence.
FTC Act, 15 U.S.C. 41 et seq.
What FDA wants
FDA asks SafaLab to immediately stop selling any unapproved, unauthorized COVID-19 products and to email CFSAN and CDER within 48 hours describing the specific steps taken and how recurrence will be prevented. FTC separately asks for an email within 48 hours to Richard Cleland describing actions taken to address its concerns.
Who should pay attention
- dietary supplement companies making health claims
- online retailers and marketplaces selling COVID-19 products
- consumers considering COVID-19 prevention supplements
This is a summary. Read the original letter on fda.gov.